BioCryst Pharmaceuticals Granted Orphan Drug Designation For The Treatment Of Fibrodysplasia Ossificans Progressiva

RumbleON (NASDAQ:RMBL) reported quarterly earnings of $0.27 per share which missed the analyst consensus estimate of $0.65 by 58.46 percent. This is a 108.31 percent increase over losses of $(3.25) per share from the